Information about technologies on neurological and psychiatric diseases (IPC A61B5, G16 and H04, LOC 24) was retrieved and collected by International Patent Classification (IPC) and Locarno Classification (LOC). The date of data retrieval and download was September 1, 2019, and a total of 328 valid relevant patents were obtained.

The search keywords were psychosis, rehabilitation, psychology, rehabilitation training, rehabilitation resource survey, mental illness, mental trauma, psychological care, alzheimer’s, schizo, autism, anxiety, depressed, paranoid, manic, commit suicide, and so on. The retrieval type was “or.” First, all patent data were converted into plain text format and directly imported into a professional data analyzer (Thomson Data Analyzer [TDA]). The data were then cleaned, integrated, and analyzed. We adopted patentometric analysis and visualization to investigate the global technology development trends in the field of neurological and psychiatric disorders based on the following: patent application, distribution of patent priority countries, major patentees, hot technologies, patent citations, and so on.

A total of 328 patents related to neurological and psychiatric diseases were retrieved from 16 countries (regions), including 191 applications for inventions, 104 grants for inventions, 16 designs, and 17 utility models. Trend analysis was performed on the number of patent applications submitted annually (Figure 1). In the past 10 years, the number of patent applications related to the prevention and treatment of neurological and psychiatric disorders has generally increased year by year. However, the number of relevant patent applications was relatively small and the growth rate was relatively low (Figure 1). From 2015 onward, the growth rate began to accelerate and subsequently the number of applications submitted began to rise rapidly. From 2000 to 2004, the number of patent applications for neurological and psychiatric diseases was relatively low and was in the first stage (Figure 1). The second phase was from 2004 to 2015, and the number of applications increased to a certain extent. Since 2015, it has been in the third stage, and the number of applications has doubled from the previous stage.

If an applicant files a patent application for his invention in one country for the first time and then files a patent application for the same subject matter in another country within the statutory period, the date of the first patent application shall be used as the filing date for the subsequent application according to the relevant law, so as to exclude the possibility of copying the patent in other countries and filing a pre-emptive application to obtain registration. By analyzing the distribution of patent priority countries, the attention and technical strength of various countries in this field can be deduced. Figure 2 shows the global regional distribution of the patent applications for neurological illness and psychiatric disorders. Since 2000, patent applications in this area have mainly come from China, the United States, and Russia. Among them, China and the United States are the front runners (or form the first echelon). The United States, which was the first country to introduce community-based prevention and treatment for patients with psychiatric disorders, developed community psychiatric rehabilitation technologies earlier than China and other countries. After more than 40 years of practice, community service has developed rapidly and achieved good results. China followed suite, occupying the second place, and currently has the largest number of patents. Russia, South Korea and Japan, as the second echelon, have submitted relatively few applications. France, Germany, India, Ukraine, the Soviet Union, Brazil, Canada, Europe, and the United Kingdom are in the third tier with even fewer applications. As for the distribution of patent priority countries, China leads the race and currently holds many core patents. As neurological and psychiatric disorders are common chronic noncommunicable diseases, and because China emphasizes on chronic disease management and continuous improvement of the medical security system, Chinese technologies for neurological and psychiatric diseases are showing a trend of continuous progress.

An analysis of those holding patents (ie, patent holders) on technologies useful for treating neurological and psychiatric disorders and the identification of major application agencies in this field can provide a strategic basis for interagency cooperation and competition. Visicu headquartered in Baltimore, Maryland, ranks second in the number of applications submitted and is the largest transferee of related patents in the world. As a clinical IT service provider and medical monitoring system developer, the company mainly develops and applies remote patient monitoring and diagnostic support technologies. Visicu was acquired by Royal Philips in 2008 (with the acquisition estimated to be 30 times the income before interest, taxes, depreciation, and amortization calculation). As can be seen from Table 1, Visicu’s applications are all US patents, most of which were filed in 2005 [10-19]. The major applications were A61B (diagnosis, surgery, and identification), G06F (electric digital data processing), and G08B (signaling or calling systems, order telegraphs, and alarm systems), which refer to electric digital data processing for diagnosis or surgery, and identification of medical and hygienic human necessities. Those are basically consistent with the technical distribution of relevant US patents.

The most frequently cited patent of Visicu is US7395216B2 [13], which uses predictive models to continuously update treatment plans for patients in different health care locations. The system comprises a database of patient data elements indicative of a medical condition associated with a patient. A predictive model is applied to patient assessment data and used to prepare a treatment plan. A rules engine applies a patient rule consistent with the treatment plan to selected data elements stored in the database to produce an output indicative of a change in the medical condition of the patient. The output from the rules engine is used to determine whether intervention is warranted. The predictive model is applied continuously to determine whether to update the treatment plan and, if necessary, the patient rule.

According to the life cycle diagram of patents (Figure 5), since 2000, neurological and psychiatric disorders have not been an important area of focus. From 2000 to 2005, the number of patent applications and applicants in this field were relatively small, hovering up and down. At this time, few people showed solicitude for this field. Earlier patent applications in the United States related to methods and apparatuses for measuring indices of brain activity during motivational and emotional functions, which directly determines the composition and degree of the motivational and emotional brain circuitry response. This circuitry response answered questions focusing on normal and abnormal behavior, along with questions regarding the normal and abnormal functions of the circuitry. The results obtained by interrogating the motivational and emotional circuitry can be used for objectively measuring, in human or animal individuals, one’s preferences toward or responses to motivationally salient stimuli including but not limited to those that are internal or external, conscious or nonconscious, pharmacological or nonpharmacological therapies, disease- or non-disease–based processes, financial or nonfinancial, etc.

Between 2005 and 2015, the number of patent applicants has increased to a certain extent, but the number of patents has not risen significantly, suggesting that although more applicants paid attention to neurological and psychiatric diseases, the technology has not made much progress. Since 2015, with increasing public concerns for this field, and based on the development of big data and internet platform technologies, the patent field has begun to undergo certain transformations. Therefore, the number of applicants and applications for related patents has witnessed a sharp rise since. The most recent application (US20190200915) was on digital biomarkers for cognition and movement diseases or disorders, which assessed a cognition and movement disease or disorder in an individual suspected to have one [23]. A cognitive or fine motoric activity parameter was determined from a data set of activity measurements obtained from the individual using a mobile device. The determined activity parameter was compared with a reference, and the cognition and movement disease or disorder was assessed. A method for identifying whether an individual will benefit from a therapy for a cognition and movement disease or disorder was also disclosed. The steps just described are performed along with the step for identifying the individual as one who will benefit from the therapy if the cognition and movement disease or disorder is assessed. A mobile device was revealed as well, comprising a processor, at least one sensor, a database, and software that is tangibly embedded in the said device and when installed on the said device performs the disclosed methods.

Research and development on patents for neurological and psychiatric disorders are significantly influenced by government policies and the market. Therefore, the number of applications and applicants will grow each time when this field is favorably affected. This means that neurological and psychiatric diseases remain in the focus of scientific and technological development, and professionals are still very much interested in it.

China, as the country with the largest number of patents related to technologies on neurological and psychiatric diseases, has 107 related patents, which mainly focus on A61B and G16H. Jilin Longjin Technology Co., Ltd., the applicant with the most patents on this topic in the world, is headquartered in China. China has not only applied for many invention patents, but also applied for 11 utility model patents and 15 appearance designs. Most global utility models and appearance design patents for community psychiatric rehabilitation are in fact Chinese patents. However, the authorization rate of invention patents in China remains very low, which may be because most patents in China were only proposed after 2015 and are thus still in the substantive examination stage. Although China had put forward relevant theories later than the United States and other Western countries, it has caught up and currently occupies a large market. The number of patents for neurological illness and psychiatric disorders in the United States is second only to that in China, with a total of 85, but all of these are invention applications with a high authorization rate. Besides A61B, the United States focuses on G06F, which is slightly different from that of China. Russia closely follows the United States, being the third country with 46 related patents, which is only about half of the number of US patents. The per-capita patent applications of Russian applicants are extremely low, with only 1 applicant applying for 3 patents and the rest applying for only 1 patent. Furthermore, unlike China and the United States, Russia’s patents are mainly focused on medical diagnosis and medical devices. There are no patents involving mobile devices.

The global development of technologies on neurological and psychiatric disorders shows the following characteristics: (1) The technology is increasingly mature. The number of patent applications in recent years has remained at a high level. Inventions and innovations are very active, with China currently being the largest patent priority country. (2) European and American companies, with a strong independent innovation capability, have considerable advantages in the area of research and development. The distribution of patent holders in China remains relatively scattered, with no technology monopoly organization at present. It is thus necessary to strengthen the collaboration between production, teaching, and research. (3) The types of patent applications worldwide are mainly invention patents. A few countries such as China and Russia have applied for a small number of utility model patents. (4) Patents mainly pertain to A61B (ie, medical and hygienic fields). By 2011, the classification number G16H (ie, health care informatics) was added, and eventually patents about internet-related mobile terminal platforms began to appear. The number of applications has increased year by year. As a newly emerging technology, there is still however great room for its development. From the special perspective of patents, this paper investigated the key technologies and development directions of industries as well as the technology combination and technology investment trends of major competitors for enterprises or countries, so as to establish technology research and application strategies on neurological and psychiatric diseases.

This paper had certain limitations. Because of the large number of patents involving neurological and psychiatric diseases, it is impossible to make a detailed interpretation of the contents of each document. Therefore, this study focused on the key technical points, categories, and regions of the patents, and illustrated the layout of the patents based on the primary and secondary technical points of the cluster diagram.

Based on this analysis, we concluded the following: (1) The United States, as a relatively mature country in the development of existing technologies, can focus its attention on further development in this area. (2) Technologies on neurological and psychiatric disorders in China have a low authorization rate for invention patents. It is thus suggested to improve the quality of Chinese patent applications and submit high-value patents. (3) In Russia, the number of patent applications on neurological and psychiatric diseases is generally small, but the authorization rate is extremely high, and therefore these need to be tracked.